Pour savoir comment effectuer et gérer un dépôt de document, consultez le « Guide abrégé – Dépôt de documents » sur le site Web de la Bibliothèque. Pour toute question, écrivez à corpus@ulaval.ca.
 

Publication :
Patient perspectives on the role of community pharmacists for antidepressant treatment : a qualitative study

bul.description.provenancelf spbfr
bul.rights.dateAccepPubl2018-02-09fr
bul.rights.periodeEmbargoP0Mfr
bul.rights.typeDatedatePublicationfr
dc.contributor.authorGrégoire, Jean-Pierre
dc.contributor.authorGuillaumie, Laurence
dc.contributor.authorNdayizigiye, Alice
dc.contributor.authorLauzier, Sophie
dc.contributor.authorBeaucage, Clément
dc.contributor.authorVilleneuve, Denis
dc.contributor.authorMoisan, Jocelyne
dc.date.accessioned2019-03-01T21:34:53Z
dc.date.available2019-03-01T21:34:53Z
dc.date.issued2018-02-09
dc.description.abstractObjectives : Patients prescribed antidepressant drug treatment (ADT) for major depression report several needs in relation to their treatment, and a large proportion of these patients will end ADT prematurely. Community pharmacists may play an important role in monitoring ADT and supporting these patients. However, little is known about patient experiences of the services provided in community pharmacies. The objectives of this study were to 1) explore patients’ experiences with the services community pharmacists provide for ADT and 2) identify potential avenues for improvement of pharmacists’ services within the context of ADT. Methods : A qualitative descriptive exploratory study was conducted among individuals diagnosed with major depression who had initiated ADT at some point in the 12 months prior to their participation in the study. A total of 14 persons recruited in a local health centre and a community-based organization participated in individual interviews. A thematic analysis of the interview transcripts was conducted. Results : Pharmacists tend to concentrate their involvement in treatment at initiation and at the first refill when questions, uncertainties and side effects are major issues. Patients felt that the pharmacists’ contributions consisted of providing information and reassurance; in these respects, their needs were met. Participants had few ideas as to what additional services pharmacists could implement to improve patients’ experience with ADT. Patients’ sole expectations were that pharmacists extend this information role to the whole length of the treatment and enhance the confidentiality of discussions in pharmacy. Conclusion : Pharmacists should provide counselling throughout the entire treatment rather than passively waiting for patients to ask their questions. However, facilitation of open discussions may not be achieved unless confidentiality at pharmacies is secured.fr
dc.identifier.doi10.1177/1715163518755814fr
dc.identifier.issn1715-1635fr
dc.identifier.urihttp://hdl.handle.net/20.500.11794/33889
dc.languageengfr
dc.publisherCanadian Pharmacists Associationfr
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.subject.rvmAntidépresseursfr
dc.subject.rvmServices pharmaceutiques communautairesfr
dc.subject.rvmDépressifs -- Soinsfr
dc.titlePatient perspectives on the role of community pharmacists for antidepressant treatment : a qualitative studyfr
dc.typearticle de recherche
dc.type.legacyCOAR1_1::Texte::Périodique::Revue::Contribution à un journal::Article::Article de recherchefr
dcterms.bibliographicCitationCanadian Pharmacists Journal CPJRPC, Vol. 151 (2), 142-148 (2018)fr
dspace.accessstatus.time2024-03-16 18:15:28
dspace.entity.typePublication
relation.isAuthorOfPublication016a13d9-e96b-42b8-a655-332894a0eee2
relation.isAuthorOfPublication242bdf75-b82c-45d5-b453-2f055e2acb1e
relation.isAuthorOfPublication49aaf59b-34f5-474e-8d4d-6e960ee268ad
relation.isAuthorOfPublicationa5d38f79-9205-4100-9e2a-d8b0d8f0843e
relation.isAuthorOfPublicationb4cf9cff-afbd-462a-abc4-bca48e544532
relation.isAuthorOfPublicationc3bd79d1-114b-4106-9546-3521580e15e5
relation.isAuthorOfPublication.latestForDiscovery016a13d9-e96b-42b8-a655-332894a0eee2
relation.isResourceTypeOfPublication4c433ef5-3937-4530-8252-cca17d715747
relation.isResourceTypeOfPublication.latestForDiscovery4c433ef5-3937-4530-8252-cca17d715747
rioxxterms.project.funder-nameAstraZeneca Canadafr
rioxxterms.project.funder-nameFonds de Recherche du Québec - Santéfr
rioxxterms.project.funder-nameMerckfr
rioxxterms.project.funder-namePfizerfr
rioxxterms.versionAccepted Manuscript (AM)fr
rioxxterms.version-of-recordhttps://doi.org/10.1177/1715163518755814fr

Fichiers

Bundle original
Voici les éléments 1 - 1 sur 1
En cours de chargement...
Vignette d'image
Nom :
CPH article alice PSDT patients 2018.pdf
Taille :
319.49 KB
Format :
Adobe Portable Document Format